COPD Market Poised for ‘Paradigm Shift’ with Potential Approvals in 2024

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Mar 27, 2024 at 11:42 AM.

  1. #1 cafead, Mar 27, 2024 at 11:42 AM
    cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    33,075
    Likes Received:
    3
    via Potential FDA approvals this year of Sanofi and Regeneron’s Dupixent (dupilumab), as well as Verona Pharma’s ensifentrine, could change the treatment paradigm for chronic obstructive pulmonary disease, according a new report from analytics firm GlobalData.

    article source
     
    Quote

Reply to Thread